These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma. Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425 [TBL] [Abstract][Full Text] [Related]
44. Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma. Zemanova M; Scudla V; Adam Z; Gregora E; Pour L; Minarik J; Pavlicek P; Pika T; Bacovsky J Neoplasma; 2008; 55(4):345-9. PubMed ID: 18505347 [TBL] [Abstract][Full Text] [Related]
45. Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. Minnema MC; van de Donk NW; Zweegman S; Hegenbart U; Schonland S; Raymakers R; Zijlmans JM; Kersten MJ; Bos GM; Lokhorst HM Bone Marrow Transplant; 2008 May; 41(9):779-84. PubMed ID: 18195681 [TBL] [Abstract][Full Text] [Related]
47. Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma. Morris TC; Kettle PJ; Drake M; Jones FC; Hull DR; Boyd K; Morrison A; Clarke P; O'Reilly P; Quinn J Br J Haematol; 2008 Nov; 143(3):349-54. PubMed ID: 18759764 [TBL] [Abstract][Full Text] [Related]
48. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. Sidra G; Williams CD; Russell NH; Zaman S; Myers B; Byrne JL Haematologica; 2006 Jun; 91(6):862-3. PubMed ID: 16769594 [TBL] [Abstract][Full Text] [Related]
49. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. Spencer A; Prince HM; Roberts AW; Prosser IW; Bradstock KF; Coyle L; Gill DS; Horvath N; Reynolds J; Kennedy N J Clin Oncol; 2009 Apr; 27(11):1788-93. PubMed ID: 19273705 [TBL] [Abstract][Full Text] [Related]
50. Recent advances in the mangement of multiple myeloma. Kumar L; Vikram P; Kochupillai V Natl Med J India; 2006; 19(2):80-9. PubMed ID: 16756196 [TBL] [Abstract][Full Text] [Related]
51. Lenalidomide: a new therapy for multiple myeloma. Palumbo A; Miguel JS; Sonneveld P; Moreau P; Drach J; Morgan G; Einsele H Cancer Treat Rev; 2008 May; 34(3):283-91. PubMed ID: 18230411 [TBL] [Abstract][Full Text] [Related]
52. Role of allogeneic stem cell transplantation in multiple myeloma. Thomson KJ; Peggs KS Expert Rev Anticancer Ther; 2005 Jun; 5(3):455-64. PubMed ID: 16001953 [TBL] [Abstract][Full Text] [Related]
53. Role of stem cell transplantation. Harousseau JL Hematol Oncol Clin North Am; 2007 Dec; 21(6):1157-74, x. PubMed ID: 17996593 [TBL] [Abstract][Full Text] [Related]
54. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Jagannath S; Barlogie B; Berenson JR; Siegel DS; Irwin D; Richardson PG; Niesvizky R; Alexanian R; Limentani SA; Alsina M; Esseltine DL; Anderson KC Br J Haematol; 2008 Nov; 143(4):537-40. PubMed ID: 18783399 [TBL] [Abstract][Full Text] [Related]
55. [Management of multiple myeloma]. Di Raimondo F; Pennisi A; Bari A; Fiumara P; Palumbo GA G Ital Nefrol; 2005; 22 Suppl 33():S46-52. PubMed ID: 16419006 [TBL] [Abstract][Full Text] [Related]
56. Recent advances in the management of multiple myeloma. Kumar L; Verma R; Radhakrishnan VR Natl Med J India; 2010; 23(4):210-8. PubMed ID: 21192514 [TBL] [Abstract][Full Text] [Related]